Compare RAPP & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RAPP | OCSL |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2024 | 2008 |
| Metric | RAPP | OCSL |
|---|---|---|
| Price | $29.66 | $13.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $46.60 | $14.33 |
| AVG Volume (30 Days) | 388.2K | ★ 596.7K |
| Earning Date | 11-06-2025 | 11-18-2025 |
| Dividend Yield | N/A | ★ 11.72% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $316,801,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $34.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.43 | $12.44 |
| 52 Week High | $42.27 | $16.50 |
| Indicator | RAPP | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 51.50 |
| Support Level | $26.92 | $13.51 |
| Resistance Level | $30.44 | $13.76 |
| Average True Range (ATR) | 1.80 | 0.23 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 90.28 | 68.38 |
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.